Minerva Neurosciences
Waltham, Massachusetts, United States · Biopharma, Biotechnology, Health Care
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development of therapies to treat patients suffering from neuropsychiatric diseases. The company's lead drug, roluperidone, is being developed to address the negative symptoms of schizophrenia, which represent a significant unmet medical need. With a commitment to advancing innovative treatments, Minerva aims to imp
Key facts
- Headquarters
- Waltham, Massachusetts, United States
- Employees
- 8
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (NERV)
- Website
- minervaneurosciences.com
- Company page
Recent activity at Minerva Neurosciences
- : SEC 8-K (5.02): On August 10, 2026, Minerva Neurosciences, Inc. appointed Anthony Aliquo as Chief Accounting Officer and principal accounting officer, effective immediately. Aliquo was previously the Vice President, Controller of the Company and has extensive accounting experience, including prior roles at BDO USA and Deloitte & Touche. In conjunction with this promotion, the Board approved an increase in his annual base salary to $296,696 and revised his performance bonus target to 35% of his salary. Fred Ahlholm, the Chief Financial Officer, will continue in his role while ceasing to be the principal accounting officer, creating a clear delineation in the financial leadership structure.
- : SEC 8-K (1.01): On May 27, 2026, Minerva Neurosciences, Inc. entered into a Sales Agreement with Leerink Partners LLC for an 'at-the-market' offering program. Under this Agreement, the Company plans to issue and sell shares of its common stock, with an aggregate offering price of up to $75.0 million. Sales will occur through the Agent based on the Company's instructions, with the Agent earning a 3.0% commission on gross proceeds. The Company retains the discretion to sell any amount of shares and may suspend or terminate the Agreement under specified conditions. This strategy allows flexible capital raising through the ongoing sale of shares in accordance with SEC regulations and market conditions.
- : SEC 8-K (8.01):
- : Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO
- : SEC 8-K (5.02): On March 30, 2026, Minerva Neurosciences, Inc. entered into a Settlement Agreement with Geoffrey Race, the President of the Company, who resigned effective March 31, 2026. The Company agreed to a severance payment including a one-time payment of Mr. Race's annual salary, 12 months of pension contributions, and a pro-rated 2026 bonus. Additionally, Mr. Race will receive £30,000 as a severance payment and other benefits. His outstanding stock options will vest immediately, and the exercise period for these options will be extended until January 1, 2030. Following his resignation, a Consultancy Agreement was established, commencing April 15, 2026, for consulting fees of £333 per hour for at least 35 hours monthly, possibly with additional stock options. This settlement indicates a significant change in the executive management of the Company, which may impact its governance and strategic direction.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On December 22, 2025, Minerva Neurosciences, Inc. held its 2025 Annual Meeting of Stockholders where significant decisions were made. The stockholders approved an amendment to the 2013 Equity Incentive Plan, increasing the number of shares authorized for issuance by 12,500,000. Additionally, two directors were elected to the Board to serve until the 2028 annual meeting. This meeting was pivotal for corporate governance and stockholder engagement, reflecting important strategic operational adjustments in the company's equity structure.
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On October 21, 2025, Minerva Neurosciences, Inc. entered into a securities purchase agreement with certain accredited investors to sell 80,000 shares of Series A Convertible Preferred Stock at a price of $1,000 per share, along with warrants to acquire additional shares. The aggregate offering price is expected to reach up to $200 million, with the closing of the transaction projected for around October 23, 2025, contingent on customary closing conditions. The warrants are structured with specific terms, including the possibility of conversion into common stock and specific conditions related to the company's clinical trial milestones in schizophrenia treatment, significantly impacting Minerva's funding and strategic initiatives.
- : Minerva Neurosciences Announces Financing of up to $200 Million, Led by Vivo Capital, to Advance Its Schizophrenia Drug Roluperidone.
Minerva Neurosciences funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Funding Round | $200.0M |
| Mar 2016 | Seed | $1.0M |
Leadership
- Fouzia Laghrissi-Thode, Director
- David Kupfer, Director
- Nico Vandervelpen, Director
- Francesco Rubertis, Director
- Remy Luthringer, Executive Officer, Director
- Michele Ollier, Director
- Jan Heek, Director
- Marc Beer, Director
- Anthony Aliquo, Vice President, Controller
- Sheila O’Connor, Chief Executive Officer
- Frederick Ahlholm, Chief Financial Officer
- Michael Davidson, Chief Medical Officer
Verified email and direct lines for Minerva Neurosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Minerva Neurosciences files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Minerva Neurosciences in the news
- Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia - The Manila Times (Oct 28, 2026)
- Minerva Neurosciences Establishes Scientific Advisory Board - GlobeNewswire (Jun 01, 2026)
- Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - Yahoo Finance (May 05, 2026)
- Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates - GlobeNewswire (Aug 07, 2026)
- Minerva Neurosciences Announces First Patient Screened in - GlobeNewswire (Mar 31, 2026)
- Minerva Neurosciences Announces Financing of up to $200 - GlobeNewswire (Oct 21, 2025)
Companies similar to Minerva Neurosciences
- Santhera Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, pharmaceuticals, Therapeutics
- Pfizer · Biopharma, Biotechnology, Health Care, Pharmaceutical, pharmaceuticals, Therapeutics
- Poolbeg Pharma plc · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- GenNeuro · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Vincerx Pharma · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Minerva Neurosciences: questions and answers
What does Minerva Neurosciences do?
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development of therapies to treat patients suffering from neuropsychiatric diseases. The company's lead drug, roluperidone, is being developed to address the negative symptoms of schizophrenia, which represent a significant unmet medical need. With a commitment to advancing innovative treatments, Minerva aims to imp
Where is Minerva Neurosciences headquartered?
Minerva Neurosciences is headquartered in Waltham, Massachusetts, United States.
How many employees does Minerva Neurosciences have?
Minerva Neurosciences has about 8 employees.
Has Minerva Neurosciences raised funding?
Yes. Fundz has recorded 2 funding events for Minerva Neurosciences. The most recent, Funding Round of $200.0M, was in Oct 2025.
Who leads Minerva Neurosciences?
Anthony Aliquo is a Vice President, Controller at Minerva Neurosciences.
What is the latest news on Minerva Neurosciences?
On Aug 12, 2026, SEC 8-K (5.02): On August 10, 2026, Minerva Neurosciences, Inc. appointed Anthony Aliquo as Chief Accounting Officer and principal accounting officer, effective immediately. Aliquo was previously the Vice President, Controller of the Company and has extensive accounting experience, including prior r
Is Minerva Neurosciences a public company?
Yes. Minerva Neurosciences is publicly traded under the ticker NERV.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy